Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
21 March 2023 - 6:01PM
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a
molecular genetics diagnostic company specializing in the early
detection of cancer, announced that Bill Caragol, the Company’s
CFO, will present and host one-on-one meetings with investors at
the Sidoti March Virtual Investor Conference, taking place on March
22-23, 2023.The presentation will begin at 12:15 ET on March
22, 2023 and can be accessed live
here:https://sidoti.zoom.us/webinar/register/WN_apzthw9PRlOrUq5PSD5Dcw.Mainz
Biomed will also host virtual one-on-ones with investors on
Wednesday and Thursday, March 22-23, 2023. To register for the
presentation or one-on-ones, visit www.sidoti.com/events.
Registration is free and you don't need to be a Sidoti
client.
About Sidoti & CompanyFor over two
decades, Sidoti & Company (http://www.sidoti.com) has been a
premier provider of independent securities research focused
specifically on small and microcap companies and the institutions
that invest in their securities, with most of its coverage in the
$100 million-$5 billion market cap range. The firm’s approach
affords companies and institutional clients a combination of
high-quality research, a small- and microcap-focused nationwide
sales effort, broad access to corporate management teams, and
extensive trading support. Sidoti serves 500+ institutional clients
in North America.
About ColoAlert ColoAlert,
Mainz Biomed’s flagship product, delivers high sensitivity and
specificity in a user-friendly, at-home colorectal cancer (CRC)
screening kit. This non-invasive test can be indicative of tumors
as determined by analyzing tumor DNA, offering better early
detection than fecal occult blood tests (FOBT). Based on
PCR-technology, ColoAlert detects more cases of colorectal cancer
than other stool tests and allows for an earlier diagnosis (Gies et
al., 2018). The product is commercially available in select EU
countries through a network of leading independent laboratories,
corporate health programs, and via direct sales. To receive
marketing approval in the US, ColoAlert will be evaluated in the
FDA-registration trial ‘ReconAAsense’. Once approved in the US, the
Company’s commercial strategy is to establish scalable distribution
through a collaborative partner program with regional and national
laboratory service providers across the country.
About
Colorectal Cancer Colorectal cancer (CRC) is the
third most common cancer globally, with more than 1.9 million new
cases reported in 2020, according to World Cancer Research Fund
International. The US Preventive Services Task Force recommends
that screening with stool DNA tests such as ColoAlert should be
conducted once every three years starting at age 45. Each year in
the US, 16.6 million colonoscopies are performed. However, roughly
one-third of US residents aged 50-75 have never been screened for
colon cancer. This gap in screening represents a $4.0B+ total
market opportunity in the US.
About Mainz Biomed
NV Mainz Biomed develops market-ready molecular
genetic diagnostic solutions for life-threatening conditions. The
Company’s flagship product is ColoAlert, an accurate, non-invasive
and easy-to-use, early-detection diagnostic test for colorectal
cancer based on real-time Polymerase Chain Reaction-based (PCR)
multiplex detection of molecular-genetic biomarkers in stool
samples. ColoAlert is currently marketed across Europe. The Company
is running a pivotal FDA clinical study for US regulatory approval.
Mainz Biomed’s product candidate portfolio also includes PancAlert,
an early-stage pancreatic cancer screening test. To learn more,
visit mainzbiomed.com or follow us on LinkedIn, Twitter and
Facebook.
For media inquiries, please
contact press@mainzbiomed.com
In Europe:MC Services AGAnne Hennecke/Caroline Bergmann+49 211
529252 20mainzbiomed@mc-services.eu
In the US:Spectrum ScienceMelissa Laverty/Valerie Enes+1 540 272
6465mainz@spectrumscience.com
For investor inquiries, please contact
info@mainzbiomed.com
Forward-Looking StatementsCertain statements
made in this press release are “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as
“anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”,
and “project” and other similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. These forward-looking statements reflect the
current analysis of existing information and are subject to various
risks and uncertainties. As a result, caution must be exercised in
relying on forward-looking statements. Due to known and unknown
risks, actual results may differ materially from the Company’s
expectations or projections. The following factors, among others,
could cause actual results to differ materially from those
described in these forward-looking statements: (i) the failure to
meet projected development and related targets; (ii) changes in
applicable laws or regulations; (iii) the effect of the COVID-19
pandemic on the Company and its current or intended markets; and
(iv) other risks and uncertainties described herein, as well as
those risks and uncertainties discussed from time to time in other
reports and other public filings with the Securities and Exchange
Commission (the “SEC”) by the Company. Additional information
concerning these and other factors that may impact the Company’s
expectations and projections can be found in its initial filings
with the SEC, including its annual report on Form 20-F filed on May
5, 2022. The Company’s SEC filings are available publicly on the
SEC’s website at www.sec.gov. Any forward-looking statement made by
us in this press release is based only on information currently
available to Mainz Biomed and speaks only as of the date on which
it is made. Mainz Biomed undertakes no obligation to publicly
update any forward-looking statement, whether written or oral, that
may be made from time to time, whether as a result of new
information, future developments or otherwise, except as required
by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Apr 2024 to May 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From May 2023 to May 2024